Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 1.00 |
| ▸ | OSBP | P22059 | 5/20 | 1.00 |
| ▸ | OSBP2 | Q969R2 | 4/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.69 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.69 |
| ▸ | CRYAB | P02511 | 1/20 | 0.69 |
| ▸ | HMGCR | P04035 | 1/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.69 |
| ▸ | ITGAV | P06756 | 1/20 | 0.69 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | SHBG | P04278 | 1/20 | 0.63 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258467 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL17858117 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL670744 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL14420779 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL289034 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL24421641 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL6388447 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL15945372 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL20608159 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 | |
| SCHEMBL15788398 | 1.00 | RORC (1.00) | RORCOSBPOSBP2NR1H3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| WO-2024228596-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | (주) 멥스젠 | 2024-11-07 | — | — | WO | claimed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | claimed |
| US-9670244-B2 | Oxysterol compounds and the hedgehog pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-06 | — | — | US | claimed |
| US-9532994-B2 | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-03 | — | — | US | claimed |
| CN-103536921-B | The application in suppression liver cancer growth of the cholesterol metabolism thing | 中国科学院上海生命科学研究院 | 2016-08-03 | — | — | CN | claimed |
| EP-1993558-B1 | OXYSTEROL COMPOUNDS AND THE HEDGEHOG PATHWAY | UNIV CALIFORNIA (US) | 2014-07-30 | — | — | EP | claimed |
| CN-103536921-A | Application of cholesterol metabolite for inhibiting liver cancer growth | SHANGHAI INST BIOL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| US-8022052-B2 | Inhibition of PPAR gamma expression by specific osteogenic oxysterols | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-20 | — | — | US | claimed |
| US-7897588-B2 | Agents and methods for enhancing bone formation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-01 | — | — | US | claimed |
| EP-1239848-A2 | COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | University of British Columbia (CA) | 2002-09-18 | — | — | EP | claimed |
| JP-2001509165-A | — | — | 2001-07-10 | — | — | JP | claimed |
| WO-2001015676-A2 | COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-03-08 | — | — | WO | claimed |
| US-6184215-B1 | TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-06 | — | — | US | claimed |
| WO-2000049992-A2 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1019059-A1 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-19 | — | — | EP | claimed |
| US-5929062-A | COMBINATION OF ONE OR MORE OXYSTEROLS AND A SUITABLE CARRIER; ANTICHOLESTEROL AGENTS | UNIVERSITY OF WESTERN ONTARIO (CA) | 1999-07-27 | — | — | US | claimed |
| WO-1998032444-A1 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-30 | — | — | WO | claimed |
| EP-0337890-B1 | COMPLEXES FROM ANTHRALIN AND ONE STEROL, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: (FR) | 1992-03-18 | — | — | EP | claimed |
| US-4961922-A | Complexes based on anthralin and a sterol, a process for obtaining them and their use in therapeutics and cosmetics | Centre International De Recherches Dermatolociques (FR) | 1990-10-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | RORC 3704/4885OSBP 321/4885OSBP2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.